

27^{cn} INTERNATIONAL SOCIETY OF CARDIOVASCULAR PHARMACOTHERAPY ANNUAL MEETING Crowne Plaza Hotel, Bucharest, Romania 27-29 October 2022

Noninvasive evaluation of coronary flow reserve in cardiac syndrome X patient

Dr./Elsayed Abd-El-kader Elsayed MD-Cardiology, Alexandria University

Objective:

Evaluation of the coronary flow reserve in cardiac syndrome X patients, (patients with coronary microvascular disease <u>CMVD</u>) (patients with chest pain, positive exercise ECG and have normal coronary angiograms) non invasively using TTDE technique and MAPSE marker.

Methods:

This prospective study included 90 patients with suspected CAD, 60 patients with cardiac syndrome X as a <u>(patient group)</u> and 30 patients as a <u>(control group)</u> referred for treadmill exercise ECG, dobutamin stress Echocardiography DSE and transthoracic doppler Echocardiography TTDE.

<u>Result:</u>

- * Coronary flow velocity reserve <u>CFVR</u> measured by TTDE, resulted that, patient group has lower hyperemic CFR than control group.
- Treadmill exercise <u>ECG</u> data shows that patient group who have exercise time <6 min, st. segment depression
 >1.5 mm and post recovery time >6 min are highly risk patients with obstructive coronary diseases.
- * Mitral annular plane systolic excursion <u>MAPSE</u> marker in detection of CMVD resulted that, patient group has <u>lower</u> MAPSE than control group.
- * The correlation between CFVR and contractile reserve is a linear relation, as in patient group has lower CFVR so, they have also low contractile reserve.

Pharmacotherapy:

According to 2019 ESC guidelines, we should use:

- * Statins
- * Aspirin.
- * Beta blockers(BBs).
- * Calcium channel blockers (Non DHP-CCBs).
- * Angiotensin converting enzyme inhibitors (ACEi).
- * Nitroglycerin.

Conclusion:

- * TTDE is a good non invasive tool for assessment of CFVR
- * <u>MAPSE</u> marker is the future for assessment of CMVD.